Evidence map›Paper›PMID 25904829›Full record

ArticleGastroenterology & hepatology2014

Effects of statins on the risk of hepatocellular carcinoma.

Pejman G Mansourian, Masato Yoneda, M Krishna Rao, Fernando J Martinez, Emmanuel Thomas, Eugene R Schiff

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Gastroenterology & hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. NAFLD-Associated HCC: Progress and Opportunities.Journal of hepatocellular carcinoma · 2021
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Mitochondria, cholesterol and cancer cell metabolism.Clinical and translational medicine · 2016
    Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Pejman G MansourianDr Mansourian, Dr Yoneda, and Mr Rao are clinical research fellows, Dr Martinez is a gastroenterology fellow, Dr Thomas is an assistant professor, and Dr Schiff is a professor and director of the Schiff Center for Liver Diseases at the University of Miami Miller School of Medicine in Miami, Florida.
Masato YonedaDr Mansourian, Dr Yoneda, and Mr Rao are clinical research fellows, Dr Martinez is a gastroenterology fellow, Dr Thomas is an assistant professor, and Dr Schiff is a professor and director of the Schiff Center for Liver Diseases at the University of Miami Miller School of Medicine in Miami, Florida.
M Krishna RaoDr Mansourian, Dr Yoneda, and Mr Rao are clinical research fellows, Dr Martinez is a gastroenterology fellow, Dr Thomas is an assistant professor, and Dr Schiff is a professor and director of the Schiff Center for Liver Diseases at the University of Miami Miller School of Medicine in Miami, Florida.
Fernando J MartinezDr Mansourian, Dr Yoneda, and Mr Rao are clinical research fellows, Dr Martinez is a gastroenterology fellow, Dr Thomas is an assistant professor, and Dr Schiff is a professor and director of the Schiff Center for Liver Diseases at the University of Miami Miller School of Medicine in Miami, Florida.
Emmanuel ThomasDr Mansourian, Dr Yoneda, and Mr Rao are clinical research fellows, Dr Martinez is a gastroenterology fellow, Dr Thomas is an assistant professor, and Dr Schiff is a professor and director of the Schiff Center for Liver Diseases at the University of Miami Miller School of Medicine in Miami, Florida.
Eugene R SchiffDr Mansourian, Dr Yoneda, and Mr Rao are clinical research fellows, Dr Martinez is a gastroenterology fellow, Dr Thomas is an assistant professor, and Dr Schiff is a professor and director of the Schiff Center for Liver Diseases at the University of Miami Miller School of Medicine in Miami, Florida.
University of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer morbidity and mortality worldwide and is one of the few cancers that is increasing in incidence. This cancer often arises in the setting of hepatic cirrhosis; however, it can also occur in patients with chronic hepatitis B virus infection without cirrhosis. Statins have been used for many years for the prevention and treatment of cardiovascular disease. Based on recent meta-analy-ses, these lipid-lowering agents are now being investigated for a class effect observed in the prevention of carcinogenesis. There are robust data suggesting that statins can alter biochemical pathways involved in tumorigenesis and cell survival and, thus, have a protective effect by reducing the risk of development of several types of cancer. In recent years, several studies have demonstrated that statins also can specifically decrease the risk of HCC development. Because statins are underutilized in patients with preexisting liver disease, understanding the role of statins in the prevention of HCC is important, and changes in practice guidelines supporting the use of statins as chemoprotective agents may be warranted.

Indexed as

cirrhosishepatitis Bhepatitis Chepatocellular carcinomaHMG-CoA reductasenonalcoholic steatohepatitisStatins

Identifiers

PMID25904829
PMCPMC4302489
OpenAlexW2188560540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.